Medicina Fluminensis, Vol. 47 No. 4, 2011.
Review article
New anticoagulant medications
Silva Zupančić Šalek
; Referentni centar za hemofiliju i trombofiliju, Odjel za trombozu i hemostazu, Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Ana Boban
; Referentni centar za hemofiliju i trombofiliju, Odjel za trombozu i hemostazu, Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Dražen Pulanić
; Referentni centar za hemofiliju i trombofiliju, Odjel za trombozu i hemostazu, Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Abstract
Currently available anticoagulant medications are effective for the prevention and treatment of thromboembolic diseases. However, they have certain drawbacks which do not allow them to be the “ideal anticoagulants”. The decision regarding anticoagulant therapy is a very complex process, especially nowadays when many new anticoagulants are available. Such new anticoagulant drugs are developed and produced to target mostly a single coagulation factor, and they have a predictable dose response. The most important anticoagulants are direct thrombin inhibitors and factor Xa inhibitors. Selective inhibitors of specific coagulation factors represent a new class of anticoagulant agents. Comparing to the traditional, classic anticoagulant medications, the new anticoagulants are potentially more effective, safer and easier to use. The possible limitation of new anticoagulants is the lack of specific antidotes. However, they have short plasma half life, making their neutralization easier.
Keywords
anticoagulant medications; apixaban; dabigatran etexilat; fondaparinux; rivaroxaban
Hrčak ID:
76668
URI
Publication date:
1.12.2011.
Visits: 5.908 *